AusperBio Announces Positive Phase II Clinical Cure Results of AHB-137 in Treatment-Naïve Chronic Hepatitis B Patients at EASL 2026

Source: Global Times

At the recently held 2026 Annual Congress of the European Association for the Study of the Liver (EASL), AusperBio unveiled groundbreaking clinical data for AHB-137, an innovative therapy for the clinical cure of chronic hepatitis B independently developed by the company, which has drawn significant attention from the global hepatology community. Conducted for the first time in treatment-naive patients with chronic hepatitis B (hereinafter referred to as "treatment-naive CHB patients"), this study yielded remarkable results: after a finite treatment course of only 16 weeks, patients achieved not only potent and durable viral suppression following treatment discontinuation, but also a breakthrough clinical cure rate exceeding 70% among the subgroup with baseline hepatitis B surface antigen (HBsAg) levels of 100–1000 IU/mL.

Professor Qiu Yunqing, former Executive Vice President of the First Affiliated Hospital, Zhejiang University School of Medicine, and Executive Deputy Director of the National Medical Center for Infectious Diseases, stated: “The World Health Organization has set a strategic goal to ‘eliminate viral hepatitis as a public health threat by 2030,’ yet the current treatment rate hovers at only around 15–20%. One of the core challenges driving this situation is that existing mainstream treatment regimens require lifelong medication. Consequently, upon diagnosis, a significant number of patients choose to delay or even abandon treatment due to the psychological burden, financial strain, and lifestyle inconveniences associated with long-term drug therapy.”

AusperBio announced that it will fully accelerate the clinical development of AHB-137, committed to bringing this "originally developed in China" innovative therapy to the global market and injecting fresh Chinese innovative momentum into achieving the WHO’s goal of "eliminating viral hepatitis as a public health threat by 2030."